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By computer search, we identified one potential NF-kB binding site in the HPV16 long control region (LCR) at position
7554–7563 having two mismatches in comparison to the consensus NF-kB binding site of the Igk L promoter. Bandshift
experiments with nuclear extracts from HeLa cells or purified glutathione S-transferase–p65 fusion protein clearly demon-
strated that NF-kB is able to bind to this region of the LCR. However, in comparison to NF-kB binding on a consensus probe,
the affinity of NF-kB for this site is about 250-fold reduced. When mutations were introduced into this NF-kB binding site, the
activity of the LCR was increased, strongly suggesting that NF-kB was acting as a transcriptional repressor in the context
of the HPV16 LCR. In addition, overexpression of NF-kB p65 repressed the activity of the HPV16 LCR, strengthening this
conclusion. © 2000 Academic Press
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iINTRODUCTION
Epidemiological and experimental studies have indi-
cated that specific high-risk types of human papilloma-
virus (HPV), especially HPV types 16 and 18, contribute to
the pathogenesis of cervical cancer (zur Hausen, 1996).
The HPV E6/E7 early genes play a pivotal role in tumor
development and also in the proliferation of cervical
carcinoma cell lines. The abilities of E6/E7 proteins of
high-risk HPV types to alter the function of cellular reg-
ulatory proteins such as the tumor suppressor proteins,
p53 and pRb, are important progression factors contrib-
uting to chromosomal instability and the development of
cell immortality. The regulation of HPV gene expression
is complex and controlled by cellular and viral transcrip-
tion factors. The transcription of the early region of HPV
16 is initiated at the p97 promoter and is regulated by the
long control region (LCR). Many cellular transcription
factors, including AP-1, C/EBPb, nuclear factor 1 (NF-1),
c-myb, Sp1, TEF-1, PEF-1, Oct-1, and YY-1, have been
reported to either activate or inhibit the HPV 16 LCR
(Chong et al., 1990, 1991; Apt et al., 1993; Tan et al., 1994;
shiji et al., 1992; Sibbet et al., 1995; Nu¨rnberg et al., 1995;
’Connor et al., 1996; Struyk et al., in press). Various
mmunoregulatory and hormonal factors, such as tumor
ecrosis factor (TNF), interleukin-1, interferons, steroid
ormone, and retinoic acid, have been reported to mod-
late HPV transcription (Kyo et al., 1994; Woodworth et
l., 1995; Bartsch et al., 1992; Creek et al., 1995; Khare et
l., 1996; Chan et al., 1989; Chong et al., 1990).
A transcription factor that plays a pivotal role in many1 To whom correspondence and reprint requests should be ad-
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40cellular responses to environmental changes, such as
virus infections, is NF-kB. NF-kB exists as homo- or as
heterodimers of a family of structurally related proteins.
Each member of this family possesses a conserved
NH2-terminal Rel homology domain, in which the DNA
inding domain, dimerization domains, and the nuclear
ocalization signal are located. To date, five proteins
elonging to the NF-kB family have been identified in
mammalian cells: p65/RelA, p50/p105, c-Rel, RelB, and
p52/p100. NF-kB dimers are sequestered in the cytosol
of unstimulated cells via noncovalent interactions with
inhibitory proteins called IkBs. The specific interaction
between the ankyrin repeats of IkBs and the Rel homol-
ogy domain of NF-kB masks the nuclear localization
signal of NF-kB and therefore prevents its translocation
to the nucleus. Signals that induce NF-kB activity cause
the phosphorylation of IkBs at Ser residues. This labels
the IkBs for ubiquitinilation and subsequently for degra-
ation, allowing NF-kB dimers to translocate into the
ucleus and to regulate gene expression (May and
osh, 1998; Stancovski and Baltimore, 1997; Woronicz et
l., 1997). NF-kB can be activated by cytokines such as
interleukin-1 (IL-1) and tumor necrosis factor (TNF) and
by pro-apoptotic and necrotic stimuli such as oxygen
free-radicals and UV light (Baeuerle and Henkel, 1994).
The activity of NF-kB is also regulated by its interaction
ith other transcription factors such as AP-1 and
/EBPb. These two latter proteins belong to the bZIP
lass of DNA binding proteins characterized by a leucine
ipper structure and an adjacent basic DNA binding
omain. Their bZIP region has been reported to directly
nteract with the Rel homology domain of NF-kB (LeClair
et al., 1992; Stein et al., 1993). Although the NF-kB/Rel
transcription factors act generally as transcriptional ac-
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41NF-kB SITE IN HPV16 LCRtivators, they also have been reported as transcriptional
repressors (Supakar et al., 1995; Wissink et al., 1997).
In this report, we have examined the involvement of
NF-kB in HPV16 LCR activity. Our data indicate that
NF-kB can bind the HPV16 LCR and acts as a transcrip-
tional repressor in the context of the HPV16 LCR.
RESULTS
NF-kB binds the HPV16 LCR
To investigate whether NF-kB is able to bind to the
PV16 LCR, a computer search for potential NF-kB bind-
ng sites was performed. Several potential binding sites
ere found; one had only two mismatches in comparison
o the consensus NF-kB binding site from the Igk L
promoter (GGGRNNYYCC; see Table 1). Bandshift exper-
iments using double-stranded oligonucleotides from the
HPV16 LCR (nt 7550 to 7576: wtLCR7550 probe) and
nuclear extracts from HeLa cells, which were transfected
with p65 in order to increase the NF-kB activity, showed
that a complex similar to the complex with the consen-
sus NF-kB probe can be observed (see Fig. 1, lanes 1
and 7). This complex is absent in the presence of a
60-fold excess of cold consensus NF-kB oligonucleotide
see Fig. 1, lanes 3 and 8) and is also slightly diminished
y a 60-fold excess of cold wtLCR7550 oligonucleotide
see Fig. 1, lane 9). Furthermore, the addition of antibod-
es directed against p50 and p65 supershifts this com-
lex, indicating that it contained immunologically related
50 and p65 (see Fig. 1, lanes 4, 5, 10, and 11). In
ontrast, antibodies directed against C/EBPb were un-
T
Oligonucleotide
Oligonucleotide
wtLCR7550 59 GCG TGC CAA ATC CC
39 CA CGC ACG GTT TAG GG
wtLCR7545 59 GC CAT GCG TGC CAA ATC C
39 CG GTA CGC ACG GTT TAG G
mutLCR7545 59 GC CAT GCG TGC CAA ATg a
39 CG GTA CGC ACG GTT TAc t
NF1 cons 59 TTT TGG ATT GAA GCC AAT A
39 AAA ACC TAA CTT CGG TTA T
NF-kB cons 59 GCT TCA GAG GGG ACT TTC
39 CGA AGT CTC CCC TGA AAG
wtLCR7836 59 CAA CTG CAC ATG GGT GT
39 GG GTT GAC GTG TAC CCA CA
NF-IL6 cons 59 GGC GTC ACA TTG CAC AAT
39 G CAG TGT AAC GTG TTA
wtLCR7288 59 GGG CTT GTG TAA CTA TTG T
39 C GAA CAC ATT GAT AAC A
Note. NF-kB binding sites are underlined (the consensus NF-kB bind
written in lowercase letters. NF-1 and (potential) C/EBPb binding sitesable to supershift this complex (see Fig. 1, lanes 6 and
12). These results indicated that NF-kB can bind the ppotential NF-kB site at position 7554–7563. The heavy
band below the NF-kB complex is not shifted by the
ddition of a-p50 and a-p65, indicating that this complex
does not contain a protein that is immunologically re-
lated to p50 and p65. This complex is most probably due
to nonspecific interaction, as we observed a complex
with the same apparent molecular weight using different
probes (see also Fig. 1) and a reduced intensity with
competing unrelated oligonucleotides (data not shown).
In addition, as shown in Fig. 2, when using purified
GST–p65 we observed a strong binding to the NF-kB
onsensus probe (exposure time 4 h) and a relatively
eak binding to the wtLCR7545 probe (exposure time
days). The addition of an antibody directed against
65 supershifts the complex as observed with both
robes (see Fig. 2, lanes 3 and 7). These findings
urnish direct evidence for p65 binding to the HPV16
CR.
In view of the weak binding affinity of NF-kB on the
tLCR probe compared to the consensus NF-kB probe,
as observed in Figs. 1 and 2, we investigated the relative
affinity of NF-kB for binding to this region of the HPV16
CR. Electrophoretic mobility shift assay (EMSA) exper-
ments using the NF-kB consensus probe and nuclear
xtracts obtained from TNFa-treated HeLa cells showed
hat the NF-kB complex can be better competed (approx-
imately 250 times) by an overdose of the NF-kB consen-
sus cold oligonucleotide than by the wtLCR7545 oligo-
nucleotide (see Fig. 3). In contrast, an irrelevant oligonu-
cleotide, comprising nt 7836–7856 from the HPV 16 LCR
for Bandshift
Source
TTC CTG ACC AC 39
AAG GAC TGG 59
T TTC C 39
A AAG G 59
T TTC C 39
A AAG G 59
A A 39
T T 59 Santa Cruz Biotechnology
AG C 39
TC G 59 Sen and Baltimore, 1986
AGG G 39
TC 59 Dong et al., 1994
AAT G 39
TTA CGG 59 Santa Cruz Biotechnology
T G 39
A CGG 59 Kyo et al., 1993
is GGGRNNYYCC). The point mutations in the NF-kB binding site are
ritten in italics and in boldface type, respectively.ABLE 1
s Used
T GTT
A CAA
CT GT
GA CA
CT GT
GA CA
TG AT
AC TA
CGA G
GCT C
G TGC
C ACG
CTT
GAA
GT CA
CA GT
ing site(wtLCR 7836), did not compete for binding to the NF-kB
robe.
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42 FONTAINE ET AL.NF-kB represses the HPV16 LCR at position
7554–7563
To investigate the effect of NF-kB on the regulation of
he HPV16 LCR, mutations were introduced in the NF-kB
binding site of the LCR (mutLCR7545) (see Table 1). As
shown in Fig. 3, we observed in EMSA experiments that
NF-kB was not able to bind the mutated double-stranded
oligonucleotide.
We studied the activity of pWtLCR-Luc and pMutLCR-
Luc in two cell lines, HeLa and C33A cells. In EMSA, we
observed that nuclear extracts of C33A, even after treat-
ment with TNFa, contained very low levels of NF-kB DNA
inding activity (see Fig. 4A). Furthermore, in transient
ransfections, we observed that chloramphenicol acetyl
ransferase (CAT) expression under the control of NF-kB
promoter elements (pNF-kB–CAT construct) is very low
n C33A cells treated with TNFa compared to HeLa cells
FIG. 1. NF-kB binds wtLCR7550 oligonucleotide. EMSA using the NF
transfected with pRSVp65. Competition experiments were performed wi
lanes 3 and 8) and cold wtLCR7550 oligonucleotide (see Table 1 fo
antibodies directed against p50, p65, and C/EBPb (lanes 4–6 and 10–12
as exposed for 6 h.treated with TNFa (see Fig. 4B). It seems therefore that
HeLa cells are suitable for studying the effect of NF-kB
son the HPV16 LCR while C33A cells could be used as
control.
In transient transfected HeLa cells, which were un-
treated or treated with TNFa, the activity of pMutLCR-Luc
s at least two times higher than the luciferase activity
btained with the pWtLCR-Luc construct (see Fig. 5A). To
erify that the observed increase of luciferase activity
as due to the introduced mutations in the HPV16 LCR,
e assessed the luciferase activity driven by these two
onstructs in C33A. As expected, the pWtLCR-Luc and
MutLCR-Luc constructs exhibited a similar luciferase
ctivity in C33A cells (see Fig. 5B). This latter result
uggested that the increased luciferase activity ob-
erved in HeLa cells by introducing mutations in the
F-kB binding site at positions 7561 and 7562 of the
HPV16 LCR was due to a specific inhibition of the neg-
ative NF-kB effect on the HPV16 LCR. These results
nsensus and wtLCR7550 probe and nuclear extracts from HeLa cells
fold molar excess of cold NF-kB consensus (see Table 1 for sequence;
nce; lanes 2 and 9). Supershift experiments were performed using
eft part (lanes 1–6) was exposed for 20 h and the right part (lanes 7–12)-kB co
th a 60-
r sequetrongly suggested that NF-kB acts as a repressor on the
HPV16 LCR.
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43NF-kB SITE IN HPV16 LCRTo investigate the effect of an overexpression of p65
on the full-length HPV16 LCR, we transfected HeLa cells
together with pRSV-p65 and pWtLCR-Luc reporter con-
struct. As shown in Fig. 6, p65 represses the HPV16 LCR.
A maximal inhibition (90%) was achieved using 1 mg of
the pRSV-p65 plasmid. This result strengthened our pre-
vious observation that the HPV16 LCR is repressed by
NF-kB.
The NF-kB and NF-1 transcription factors bind
verlapping specific binding sites between nt
545–7576 of the HPV16 LCR
Computer analysis searching additional DNA binding
ites for transcription factors in the nt 7550–7576 HPV16
CR was performed. Two overlapping binding sites were
ound: a potential C/EBPb binding site containing one
ismatch compared to the C/EBPb consensus binding
sequence (eighth nt from the 59 end of this potential
C/EBPb binding site) and a half-consensus NF-1 binding
FIG. 2. Recombinant p65 binds wtLCR7545 oligonucleotide. EMSA
using the NF-kB consensus and wtLCR7545 probe and purified GST–
p65 fusion protein (1, 5, and 10 mg). Supershift experiments were
performed using antibodies directed against p65 (lanes 3 and 7). The
left part (NF-kB consensus probe) was exposed for 4 h, and the right
art (wtLCR7545 probe) was exposed for 4 days.site as previously reported by others (see Table 1) (Gloss
et al., 1989). To investigate whether C/EBPb can bind this
o
1CR, we performed bandshift experiments using a GST–
/EBPb fusion protein. An oligonucleotide starting at
nucleotide 7545 of the LCR was used to verify whether
the negative results observed with a-C/EBPb in Fig. 1
ere not due to the short space between the C/EBPb
putative binding site and the end of the oligonucleotide
(see Table 1). As shown in Fig. 7A, GST–C/EBPb bound
o the C/EBPb consensus probe (lanes 1–4), but not to
the nt 7545–7568 HPV16 LCR oligonucleotide (lanes
5–8). As shown in lane 4 of Fig. 7A, the complex binding
to the C/EBPb consensus probe was supershifted in the
resence of anti-C/EBPb antibodies, confirming that it
contained a protein that is immunologically related to
C/EBPb. The formation of the complex is inhibited in the
resence of a 60-fold excess of cold C/EBPb consensus
probe (see Fig. 7A, lane 2, and Fig. 7B, lane 2) or a 60- to
120-fold excess of a cold wtLCR 7288 oligonucleotide,
containing four C/EBPb binding sites as previously de-
scribed (Kyo et al., 1993) (see Fig. 7B, lanes 5 and 6) but
not by a 60- to 120-fold excess of a cold wtLCR7545
oligonucleotide (see Fig. 7B, lanes 3 and 4) or a cold
irrelevant LCR oligonucleotide (wtLCR 7836) (see Fig. 7A,
lane 3). These results indicate that C/EBPb does not bind
to the 7545–7568 region.
Additionally, since this region appeared to contain a
NF-1 binding site, we investigated the relative binding
affinity of NF-1 to this region of the HPV16 LCR. EMSA
experiments using the NF-1 consensus probe and nu-
FIG. 3. NF-kB binds weakly to the wtLCR7545 oligonucleotide com-
ared to the NF-kB consensus probe and NF-kB is not able to bind any
onger to the mutLCR oligonucleotide. EMSA using the NF-kB consen-
us probe and nuclear extracts from HeLa cells treated with TNFa.
ompetition experiments were performed with 0, 0.01, 0.05, 0.1, and 0.25
mol of cold NF-kB consensus oligonucleotide (lanes 1–5, respectively)
r 1, 2.5, 5, and 15 pmol of cold wtLCR7545 or mutLCR7545 (lanes 6–7,
–9, 10–11, and 12–13, respectively) and 5 pmol of a cold irrelevant
ligonucleotide, comprising nt 7836–7856 from the HPV16 LCR (lane
4).
2
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44 FONTAINE ET AL.clear extracts obtained from TNFa-treated HeLa cells
showed that the NF-1 complex can be better competed
(approximately 100 times) by an excess of the NF-1
consensus cold oligonucleotide than by the wtLCR7545
oligonucleotide (see Fig. 8A). We also observed in a
competition experiment (Fig. 8A) and in direct NF-1/DNA
binding (Fig. 8B) that NF-1 binds two times less efficiently
to the mutLCR7545 oligonucleotide than to the
wtLCR7545 oligonucleotide. These results suggested
FIG. 4. (A) NF-kB activity in HeLa and C33A cell lines. EMSA using th
without or with TNFa. Supershift experiments were performed using a
, 3 and 5, 6) and C33A (lanes 8, 9 and 11, 12) cells (untreated or treated
n HeLa and C33A cells treated without or with TNFa. The conver
independent CAT assays were performed in triplicate, all showing simi
per minute.that the 2-nt mutations introduced in this region to abol-
ish NF-kB binding seemed to affect also slightly the Abinding of NF-1. In contrast, the NF-kB consensus oligo-
nucleotide did not compete for binding to the NF-1 probe.
DISCUSSION
In the present study, we have identified a NF-kB bind-
ing site in the HPV-16 LCR promoter, localized in a region
exhibiting enhancer activity (Chong et al., 1990). This site
contains two mismatches in comparison to the consen-
B consensus probe and nuclear extracts of HeLa or C33A cells treated
es directed against p50 and p65 and nuclear extracts of HeLa (lanes
Fa). (B) Transient transfection of pSV2–CAT and pNF-kB–CAT plasmids
oducts were quantitated with a scintillation counter. At least three
lts. The results of a representative CAT assay are shown. cpm, countse NF-k
ntibodi
with TN
sion prsus NF-kB Igk binding site (Sen and Baltimore, 1986).
mong the other HPVs, only HPV7, HPV59 and HPV66
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45NF-kB SITE IN HPV16 LCRcontain a LCR with a potential NF-kB sequence also with
two mutations in comparison to the NF-kB consensus
sequence. HPV16 and HPV66 are the only high-risk gen-
ital HPV types containing a potential NF-kB binding site.
NF-kB can bind at position 7554–7563 of the HPV16
LCR as observed in EMSA experiments but with a much
lower affinity than the consensus NF-kB binding site in
the Igk promoter. In addition, we observed in EMSA that
F-1 binds an NF-1 binding site overlapping the newly
dentified NF-kB binding site. This NF-1 site was previ-
usly reported to mediate an up-regulation of the LCR
ctivity (Apt et al., 1993; Chong et al., 1990). When muta-
ions were specifically introduced into the NF-kB site of
he LCR, the binding of NF-1 to the mutated region was
educed by a factor of 2. However, the activity of the LCR
as increased two- to threefold. Therefore the higher
evel of activity of the mutant LCR-luciferase construct is
ot due to the reduction of NF-1 binding. Furthermore,
his was observed only in cells with a high level of NF-kB
ctivity, such as in HeLa cells, and not in the C33A cell
ine, in which NF-kB activity cannot be induced by TNFa
(see Fig. 4). This result suggests that NF-kB acts as a
repressor in the HPV-16 promoter context. In addition, we
observed that transient overexpression of p65 repressed
the HPV16 LCR in HeLa cells (see Fig. 6). In contrast,
overexpression of p50 had no effect on the expression of
FIG. 5. NF-kB represses the HPV16 LCR activity. Transient transfectio
reated without or with TNFa. At least three independent luciferase ass
epresentative luciferase assay are shown. RLU, relative light unit.
FIG. 6. Overexpression of NF-kB p65 represses the HPV16 LCR.
ransient transfection of pRSV-p65 and pWtLCR-Luc plasmids in HeLa
ells. At least three independent luciferase assays were performed inriplicate, all showing similar results. The results of a representative
uciferase assay are shown.the reporter construct probably because p50 does not
contain a transactivation domain (data not shown). Al-
though NF-kB is more generally known as a transcrip-
ional activator, it has been also previously reported to
ct as a transcriptional inhibitor on various promoters.
nterestingly, NF-kB and the glucocorticoid receptor have
been reported to repress each other’s transcriptional
activity (Wissink et al., 1997). These observations sug-
gest that the negative cross-talk between these two
factors could result from direct protein–protein interac-
tion and also from interference in interacting with cofac-
tors.
Although we did not elucidate the mechanisms of
HPV16 LCR repression by NF-kB, our results indicate
hat the NF-kB binding site at position 7554–7563 over-
aps with a NF-1 binding site. Therefore, it is possible
hat NF-kB competes with NF-1 for DNA binding. Due to
the weak binding affinity of NF-kB and NF-1 in this
region, we were unable to study possible competition
between these two transcriptional factors. It is also pos-
sible that NF-kB and NF-1 could compete for interaction
ith a coactivator, such as p300 or CBP. NF-kB was
indeed reported to interact with p300/CBP coactivators
(Gerritsen et al., 1997; Perkins et al., 1997) but, on the
other hand, there is no evidence for direct interaction
between NF-1 and these coactivators. However, various
reports suggest that some members of the NF-1 family
could interact directly or indirectly with the initiation
complex machinery (Martinez et al., 1991; Altmann et al.,
1994; Xiao et al., 1994; Kim and Roeder, 1994).
Although a potential C/EBPb binding site containing
only one mismatch in comparison to the C/EBPb con-
ensus site is also present in the 7545–7568 fragment,
e did not detect binding of C/EBPb to this region in
MSA. Furthermore, although C/EBPb was reported to
interact with NF-kB we did not observe in supershift
ssays an interaction between these two factors in the
ontext of nt 7545–7576 of the HPV16 LCR (see Fig. 1).
The pMutLCR-Luc, which does not bind NF-kB, is still
epressed in HeLa cells by TNFa treatment (Fig. 5). This
tLCR-Luc and pMutLCR-Luc plasmids in HeLa (A) and C33A (B) cells
re performed in triplicate, all showing similar results. The results of an of pWsuggests that the effect of TNFa on the HPV16 LCR is not
through NF-kB and that other transcription factors (like
e
L
d
p
c
s
p
p
2
), or a
(A, lan
46 FONTAINE ET AL.AP-1) are involved in HPV16 LCR inhibition by TNFa (Soto
t al., 1999). Alternative explanations are that the HPV16
CR might contain additional NF-kB sites that were not
etected in our computer search or that NF-kB could still
bind the mutated NF-kB site in the context of the com-
lete HPV16 LCR caused by a different higher order
omplex formation.
Our results clearly demonstrated that NF-kB can bind
the HPV16 LCR and that the binding of this transcription
factor at position 7554–7563 inhibits in HeLa cells the
activity of the viral promoter. The possible implications of
this finding for the viral life cycle must be evaluated in
future experiments.
MATERIALS AND METHODS
Plasmid construction
The pWtLCR-Luc luciferase reporter gene was con-
FIG. 7. C/EBPb cannot bind the wtLCR oligonucleotide. EMSA using th
rotein. Competition experiments were performed with a 60-fold molar
), a 60- and 120-fold molar excess of cold wtLCR 7288 oligonucleoti
120-fold) molar excess of cold wtLCR7545 (A, lane 6; B, lane 3 and 4
experiments were performed with antibodies directed against C/EBPbstructed by cloning the HPV16 LCR PstI–AvaII (nt 7007–
117) (Seedorf et al., 1985) fragment in front of a luciferasegene in pUHC13.3 (digested with XhoI and KpnI) (Gossen
and Bujard, 1992). The HPV16 LCR luciferase construct
with mutations in the NF-kB binding site (pMutLCR-Luc)
was constructed by PCR amplification with two different
primer sets (de Jong et al., 1992). The first primer set
included SP6-specific 59 primer (59 TTT AGG TGA CAC
TAT AGA ACT C 39) and HPV16 LCR-specific (7550–7576)
39 primer (59 GGT CAG GAA AAC AGT CAT TTG GCA
CGC 39). The second primer set included HPV16 LCR-
specific (7550–7576) 59 primer (59 GCG TGC CAA ATG
ACT GTT TTC CTG ACC 39) and T7-specific 39 primer (59
TAATACGACTCACTATAGGGAGA 39). The two PCR frag-
ments generated were pooled and subjected to a final
PCR amplification with the SP6-specific 59 primer and
T7-specific 39 primer.
The pGEX-C/EBPb and pGEX-p65 plasmids were con-
tructed by cloning a C/EBPb EcoRI fragment (from
CMV 2 C/EBPb) in pGEX5x-3 (Pharmacia Biotechnol-
ogy) and a p65 PCR fragment with a BamHI and an XhoI
Pb consensus and wtLCR7545 probe and purified GST–C/EBPb fusion
of cold C/EBPb consensus oligonucleotide (A, lanes 2 and 7; B, lane
taining four C/EBPb binding sites) (B, lanes 5 and 6), a 60-fold (and
n irrelevant LCR oligonucleotide (wtLCR 7836) (A, lane 3). Supershift
e 4 and 8).e C/EB
excess
de (consite in pGEX5x-3, respectively. All DNA constructs gen-
erated were checked by DNA sequence analysis. The
D
N
E
b
p
w
p
p
c
p
5
(
H
545 pro
47NF-kB SITE IN HPV16 LCRpNF-kB–CAT plasmid was kindly provided by N. Mukaida
(Mukaida et al., 1994).
The pRSVp65 plasmid was constructed by cloning the
p65 XbaI (blunt ended)–HindIII fragment from the pCMV-
p65 (Schmitz and Baeuerle, 1991) into the pRSVneo vec-
tor (Gorman et al., 1984) digested with HpaI and XbaI.
Cell cultures
The human cervical carcinoma cell lines HeLa and
C33A (ATCC, Bethesda, MD) were grown in Dulbecco’s
modified Eagle’s medium (Life Technologies Ltd., Paisley,
Scotland) with 10% FCS, 0.1 mg/ml streptomycin, and 100
U/ml penicillin.
Nuclear extracts
Nuclear extracts were obtained from untreated HeLa
and C33A cells, from HeLa and C33A cells treated for 15
min with 30 ng/ml TNFa, or from HeLa transfected with
pRSV-p65. The nuclear extracts were prepared as de-
scribed by Meijer et al. (1992).
Expression and purification of proteins from
Escherichia coli
E. coli C600 was transformed with pGEX–C/EBPb or
pGEX–p65. GST–fusion proteins were produced and pu-
rified as previously described by Oude Essink et al.
(1997).
The purity and identity of the proteins were determined
FIG. 8. NF-1 and NF-kB bind overlapping sites in the wtLCR oligonu
eLa cells treated with TNFa. Competition experiments were perform
2, 3, and 6, respectively) or 1, 2.5, 5, and 15 pmol of cold wtLCR7545 o
NF-kB consensus oligonucleotide (lane 1). (B) EMSA using the wtLCR7
protein containing only the DNA binding domain (1 of 3 ml).by Coomassie brilliant blue staining of a SDS–polyacryl-
amide gel and by Western blotting with antibodies di-rected against C/EBPb and p65 (Santa Cruz Technolo-
gies, Santa Cruz, CA). Bacterial recombinant NF-1 (DNA
binding domain) (Dekker et al., 1996) was a kind gift of J.
ekker and P. C. van der Vliet (University of Utrecht, The
etherlands).
lectrophoretic mobility shift assay
Double-stranded DNA oligonucleotides (2.5 pmol) (Ta-
le 1) were end-labeled with [g-32P]ATP using 2.0 ml T4
olynucleotide kinase (10 u/ml). Gel retardation assays
ere performed using equal amounts of nuclear extract
roteins (5–10 mg), 5 3 104 cpm of DNA probe, 0.5 mg
oly(dI–dC) (Pharmacia), 10 mg BSA, with or without cold
ompetitors (in a 60- to 240-fold molar excess of labeled
robe), in a final volume of 20 ml containing 10 mM
HEPES, pH 7.9, 60 mM KCl, 1 mM EDTA, 2.5 mM MgCl2,
% glycerol, 1 mM dithiothreitol. For supershifts, 2 ml of
anti-human NF-kB p50 (NFKB1), anti-NF-kB p65 (Rel A)
Rockland, Gilbertville, PA), or anti-C/EBPb (C-19) (Santa
Cruz Biotechnology) was added to the nuclear extracts at
4°C 1 h before the addition of the labeled oligonucleo-
tide.
Binding reactions were performed for 25 min at 25°C,
and the DNA–protein complexes were separated by
electrophoresis in 4% acrylamide/bisacrylamide gels in
25 mM Tris–borate, pH 8.2, 0.5 mM EDTA for 2 h at 210 V.
DNA transfection, luciferase assay, and CAT assay
5
e. (A) EMSA using the NF-1 consensus probe and nuclear extracts of
0, 0.05, and 2.5 pmol of cold NF-1 consensus oligonucleotide (lanes
R7545 (lanes 4–5, 7–8, 9–10, and 11–12, respectively) and 15 pmol of
be (lanes 1 and 2) or the mutLCR7545 probe (lanes 3 and 4) and NF-1cleotid
ed with
r mutLCApproximately 5.0 3 10 cells per 60-mm dish were
transiently transfected by the calcium phosphate method
p
w
a
a
w
D
C
C
M
48 FONTAINE ET AL.(van der Eb and Graham, 1980). Five micrograms of
pLCR-Luc (wild-type or NF-kB mutant GG 3 TC, 7554–
7555) or 2.5 mg pNF-kB–CAT reporter constructs and
0.25, 0.5, or 1, mg pRSV-p65 were used. Twenty-four
hours after transfection, fresh medium with or without
TNFa (30 ng/ml) was added. After another incubation
eriod of 24 h, lysates were prepared. Luciferase assays
ere carried out by the method of De Wet et al. (1987)
nd CAT assays were performed as described by Seed
nd Sheen (1988). All transient transfection experiments
ere performed in triplicate using different batches of
NA constructs.
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